The Claim
In high-risk patients with stable atherosclerosis who are already receiving statin therapy, the addition of the PCSK9 inhibitor evolocumab significantly reduces the risk of ischemic stroke compared to placebo, with a hazard ratio of 0.75 (95% confidence interval: 0.62–0.92) over a median follow-up period of 2.2 years, indicating a modest but statistically significant protective effect.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with clogged arteries who are already taking cholesterol drugs, adding a medicine called evolocumab can help lower their chance of having a stroke.
See the scientific wording
In high-risk patients with stable atherosclerosis who are already on statin therapy, adding the PCSK9 inhibitor evolocumab reduces the risk of ischemic stroke compared to placebo, with a hazard ratio of 0.75 (95% CI, 0.62–0.92) over a median follow-up of 2.2 years, indicating a modest but statistically significant protective effect.
What the research says
1 studyThe study shows that adding evolocumab to statins lowers the risk of ischemic stroke in high-risk patients with artery disease, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.